PULM (Pulmatrix) Debt-to-Asset : 0.00 (As of Dec. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Pulmatrix Debt-to-Asset?

Pulmatrix's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $0.00 Mil. Pulmatrix's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $0.00 Mil. Pulmatrix's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2024 was $9.94 Mil. Pulmatrix's debt to asset for the quarter that ended in Dec. 2024 was 0.00.

Pulmatrix Debt-to-Asset Historical Data

The historical data trend for Pulmatrix's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pulmatrix Debt-to-Asset Chart

Pulmatrix Annual Data

Trend

Mar15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-Asset

Get a 7-Day Free Trial

0.05

0.04

0.02

0.26

Pulmatrix Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Debt-to-Asset	Get a 7-Day Free Trial															0.26	0.28	-	-	-

Competitive Comparison of Pulmatrix's Debt-to-Asset

For the Biotechnology subindustry, Pulmatrix's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pulmatrix's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pulmatrix's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Pulmatrix's Debt-to-Asset falls into.

Save Embed

;

Save Embed

;

Pulmatrix Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Pulmatrix's Debt-to-Asset for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	9.943
	=	0.00

Pulmatrix's Debt-to-Asset for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	9.943
	=	0.00

Pulmatrix (NAS:PULM) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Pulmatrix Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Pulmatrix's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Pulmatrix Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pulmatrix Inc (NAS:PULM) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

2PU:Germany

Address

945 Concord Street, Suite 1217, Framingham, MA, USA, 01701

Website

https://www.pulmatrix.com

Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).

Executives

Peter Ludlum	officer: Interim CFO	20725 S. WESTERN AVE., SUITE 136, TORRANCE CA 90501
Margaret Wasilewski	officer: Chief Medical Officer	C/O PULMATRIX, INC., 99 HAYDEN AVENUE, SUITE 390, LEXINGTON MA 02421
Anand Varadan	director	C/O CHIASMA, INC., 60 WELLS AVENUE, NEWTON MA 02459
Todd Bazemore	director	C/O DYAX CORP., 55 NETWORK DRIVE, BURLINGTON MA 01803
Christopher Cabell	director	C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Michelle Siegert	officer: Vice President, Finance	99 HAYDEN AVENUE, SUITE 390, LEXINGTON MA 02421
Richard P. Batycky	director	C/O ACORDA THERAPEUTICS, 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Robert Nelsen	other: Former 10% owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Polaris Venture Partners Founders' Fund V, L.p.	10 percent owner	ONE MARINA PARK DRIVE, 10TH FLOOR, BOSTON MA 02210
Polaris Venture Partners Entrepreneurs' Fund V, L.p.	10 percent owner	ONE MARINA PARK DRIVE, 10TH FLOOR, BOSTON MA 02210
Polaris Venture Partners Special Founders' Fund V, L.p.	10 percent owner	ONE MARINA PARK DRIVE, 10TH FLOOR, BOSTON MA 02210
Polaris Venture Partners V, L.p.	10 percent owner	ONE MARINA PARK DRIVE, 10TH FLOOR, BOSTON MA 02210
Polaris Venture Management Co. V, L.l.c.	10 percent owner	ONE MARINA PARK DRIVE, 10TH FLOOR, BOSTON MA 02210
Jonathan A Flint	10 percent owner	1000 WINTER STREET, SUITE 3350, WALTHAM MA 02451
Polaris Venture Management Co Iv Llc	10 percent owner	ONE MARINA PARK DRIVE, 10TH FLOOR, BOSTON MA 02210